MX2015008462A - Forma de dosis monolitica para liberacion modificada de una combinacion de ingredientes activos. - Google Patents

Forma de dosis monolitica para liberacion modificada de una combinacion de ingredientes activos.

Info

Publication number
MX2015008462A
MX2015008462A MX2015008462A MX2015008462A MX2015008462A MX 2015008462 A MX2015008462 A MX 2015008462A MX 2015008462 A MX2015008462 A MX 2015008462A MX 2015008462 A MX2015008462 A MX 2015008462A MX 2015008462 A MX2015008462 A MX 2015008462A
Authority
MX
Mexico
Prior art keywords
dosage form
active ingredient
modified release
ingredient combination
monolithic
Prior art date
Application number
MX2015008462A
Other languages
English (en)
Other versions
MX370067B (es
Inventor
Karl-Heinz Przylenk
Gernot Francas
Original Assignee
Hennig Arzneimittel Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201210113098 external-priority patent/DE102012113098A1/de
Application filed by Hennig Arzneimittel Gmbh & Co filed Critical Hennig Arzneimittel Gmbh & Co
Publication of MX2015008462A publication Critical patent/MX2015008462A/es
Publication of MX370067B publication Critical patent/MX370067B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

La invención se relaciona a una forma de dosis peroral monolítica la cual permite una liberación modificada, preferentemente una liberación extendida y retrasada, de una combinación de ingrediente activo de ingredientes activos con propiedades de solubilidad que se desvían fuertemente entre sí. La forma de dosis comprende por lo menos un emulsificante con un patrón estructural de óxido de polialquileno y por lo menos un agente de liberación controlada. Usando las formas de dosis de acuerdo a la invención, incluso ingredientes activos los cuales tienen una estabilidad de almacenamiento limitada y otras propiedades de ingredientes activos desfavorables que obstaculizan adicionalmente el procesamiento pueden ser caracterizadas en una forma óptima. La invención también se relaciona a un método para producir la forma de dosis y al uso del mismo.
MX2015008462A 2012-12-27 2013-12-23 Forma de dosis monolítica para liberación modificada de una combinación de ingredientes activos. MX370067B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE201210113098 DE102012113098A1 (de) 2012-12-27 2012-12-27 Monolithische Arzneiform zur modifizierten Freisetzung einer Wirkstoffkombination
DE102013101049 2013-02-01
PCT/EP2013/077939 WO2014102253A1 (de) 2012-12-27 2013-12-23 Monolithische arzneiform zur modifizierten freisetzung einer wirkstoffkombination

Publications (2)

Publication Number Publication Date
MX2015008462A true MX2015008462A (es) 2015-09-23
MX370067B MX370067B (es) 2019-11-29

Family

ID=49911528

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008462A MX370067B (es) 2012-12-27 2013-12-23 Forma de dosis monolítica para liberación modificada de una combinación de ingredientes activos.

Country Status (19)

Country Link
US (1) US20150343067A1 (es)
EP (1) EP2938328B1 (es)
KR (1) KR102220130B1 (es)
AU (1) AU2013369379B2 (es)
BR (1) BR112015015483A8 (es)
CA (1) CA2895609C (es)
EA (1) EA032456B1 (es)
HU (1) HUE063546T2 (es)
IL (1) IL239670B (es)
LT (1) LT2938328T (es)
MX (1) MX370067B (es)
PH (1) PH12015501487B1 (es)
PT (1) PT2938328T (es)
RS (1) RS64741B1 (es)
SA (1) SA515360671B1 (es)
SI (1) SI2938328T1 (es)
UA (1) UA118099C2 (es)
WO (1) WO2014102253A1 (es)
ZA (1) ZA201505084B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2959887T (lt) * 2014-06-26 2019-03-12 Hennig Arzneimittel Gmbh&Co. Kg Vaistai galvos svaigimo, atsiradusio dėl įvairių priežasčių, gydymui
EP4136103A4 (en) 2020-04-17 2024-05-15 Hb Biotech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES
WO2022236289A1 (en) * 2021-05-05 2022-11-10 Lyndra Therapeutics, Inc. Gastric residence systems comprising methadone

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005014142B4 (de) * 2005-03-23 2006-11-09 Hennig Arzneimittel Gmbh & Co. Kg Pelletförmige Retardzubereitung gegen Schwindel
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
DE102011075354A1 (de) * 2011-05-05 2012-11-08 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur gezielten Freigabe von Wirkstoffen
EP2704698B1 (de) * 2011-05-05 2019-10-02 Hennig Arzneimittel GmbH&Co. Kg Arzneiform zur gezielten freigabe von wirkstoffen

Also Published As

Publication number Publication date
RS64741B1 (sr) 2023-11-30
KR20150100734A (ko) 2015-09-02
AU2013369379B2 (en) 2018-03-15
EA201500694A1 (ru) 2015-10-30
BR112015015483A2 (pt) 2017-07-11
PT2938328T (pt) 2023-09-26
LT2938328T (lt) 2023-11-27
EA032456B1 (ru) 2019-05-31
CA2895609A1 (en) 2014-07-03
SI2938328T1 (sl) 2023-11-30
UA118099C2 (uk) 2018-11-26
BR112015015483A8 (pt) 2019-10-22
US20150343067A1 (en) 2015-12-03
KR102220130B1 (ko) 2021-02-25
SA515360671B1 (ar) 2022-11-13
WO2014102253A1 (de) 2014-07-03
HUE063546T2 (hu) 2024-01-28
MX370067B (es) 2019-11-29
IL239670B (en) 2020-08-31
EP2938328B1 (de) 2023-07-05
CA2895609C (en) 2021-01-12
PH12015501487A1 (en) 2015-09-21
IL239670A0 (en) 2015-08-31
AU2013369379A1 (en) 2015-07-16
ZA201505084B (en) 2016-12-21
PH12015501487B1 (en) 2015-09-21
EP2938328A1 (de) 2015-11-04

Similar Documents

Publication Publication Date Title
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
PH12016501122A1 (en) Delayed release compositions of linaclotide
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
PH12015501156A1 (en) Pharmaceutical compositions
오영희 The health status of older Koreans and policy considerations
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
PH12015501096A1 (en) Composition for immediate and extended release
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
IN2013MU03583A (es)
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MD4563C1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
PH12015501487A1 (en) Monolithic dosage form for the modified release of an active agent ingredient combination
MX2016015208A (es) Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
IN2014MU00916A (es)
EP3144005A4 (en) Composition for preventing and treating male infertility, containing mixed herbal extract as active ingredient and use thereof
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2018005345A (es) Composiciones farmaceuticas de dimetil fumarato.
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
IN2014DN07895A (es)
MX2015011101A (es) Composiciones farmaceuticas de donepezilo que tienen un perfil de disolución in vitro o parámetros farmacocinéticos específicos.

Legal Events

Date Code Title Description
FG Grant or registration